Search results for 천안오피〖ȍƥsS3 1⁍nEt〗【LOVELY】ч♪오피쓰♪ 【5피쓰】천안오피✳천안마사지ತ천안오피∜천안마사지వ천안휴게텔ಙ천안휴게텔м천안오피 - 접대"target="_blank"

PHARMAC Annual Report June 2001

https://www.pharmac.govt.nz/2002/07/30/AR01.pdf

E. 59 _____________________________________________________________________________ Inaugural report of Pharmaceutical Management Agency for the six month period ended 30 June 2001 _____________________________________________________________________________ Presented to the House of Representatives...

1

https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2009-02.pdf

Cancer Treatments Subcommittee of PTAC (CaTSoP) meeting held 5 February 2009 (minutes for web publishing) The CaTSoP Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and PTAC Subcommittees 2008: Note that thi...

1

https://www.pharmac.govt.nz/assets/ptac-immunisation-subcommittee-minutes-2018-05.pdf

Immunisation Subcommittee of the Pharmacology and Therapeutics Advisory Committee (PTAC) Meeting held on 16 May 2018 (minutes for web publishing) Immunisation Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) ...

1

https://www.pharmac.govt.nz/assets/ptac-immunisation-subcommittee-minutes-2018-6.pdf

Immunisation Subcommittee of the Pharmacology and Therapeutics Advisory Committee (PTAC) Meeting held on 16 May 2018 (minutes for web publishing) Immunisation Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) ...

statement-of-performance-expectations-2016-2017.pdf

https://www.pharmac.govt.nz/assets/statement-of-performance-expectations-2016-2017.pdf

E59 PHARMAC Statement of Performance Expectations 2016–2017 Presented to the House of Representatives pursuant to Section 149L(3) of the Crown Entities Act 2004 1 PHARMAC Statement of Performance Expectations 2016-17 2 © Pharmaceutical Management Agency ISSN 2382-0780 (Print) ISSN 2382-0799 (Online)...

SPE-2017.pdf

https://www.pharmac.govt.nz/assets/SPE-2017.pdf

E.59 Pharmaceutical Management Agency Statement of Performance Expectations 2017/18 E59 PHARMAC Pharmaceutical Management Agency Statement of Performance Expectations 2017–2018 PHARMAC Statement of Performance Expectations 2017-18 This work is licensed under the Creative Commons Attribution 4.0 Inte...

Statement of Performance Expectations 2018/2019

https://www.pharmac.govt.nz/assets/statement-of-performance-expectations-2018-2019.pdf

E.59 Pharmaceutical Management Agency Statement of Performance Expectations 2018/19 PHARMAC Pharmaceutical Management Agency Statement of Performance Expectations 2018/19 Stuart McLauchlan Prof Jens Mueller Chair Board Member 29 June 2018 29 June 2018 Presented to the House of Representatives pursua...

26k003_.DOC

https://www.pharmac.govt.nz/2003/08/05/SOI2004.pdf

Pharmaceutical Management Agency (PHARMAC) Statement of Intent 1 July 2003 to 30 June 2004 M9-1-1 #72320 - 2 - TABLE OF CONTENTS PART 1 PHARMAC’S OBJECTIVES AND STRATEGIC PRIORITIES 4 PHARMAC’S Statutory Functions 4 Strategic Priorities 4 PHARMAC’s aim in 2003/04 6 Key Activities 7 PHARMAC’s Contrib...

Statement of Performance Expectations 2017/2018

https://www.pharmac.govt.nz/assets/statement-of-performance-expectations-2017-2018.pdf

E.59 Pharmaceutical Management Agency Statement of Performance Expectations 2017/18 E59 PHARMAC Pharmaceutical Management Agency Statement of Performance Expectations 2017–2018 PHARMAC Statement of Performance Expectations 2017-18 This work is licensed under the Creative Commons Attribution 4.0 Inte...

9 Results of Cost-Utility Analysis

https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/pfpa/9-results-of-cost-utility-analysis...

9 Results of Cost-Utility Analysis < previous | next > Key Recommendation: The results of cost-utility analysis should be reported as incremental utility-cost ratios (IUCRs), defined as incremental QALY gains per unit net costs. IUCRs reflect the opportunity cost of investment decisions when operati...

Microsoft Word - 2010-11 Statement of Intent - signed and final.DOC

https://www.pharmac.govt.nz/assets/statement-of-intent-2010-11-2012-13.pdf

Pharmaceutical Management Agency Statement of Intent 2010/11–2012/13 INTRODUCTION PHARMAC is well placed to meet the challenges of the current economic environment. PHARMAC has a strong track record of managing funding within budget and the skills we have used to establish this record will stand us ...

1

https://www.pharmac.govt.nz/assets/ptac-interventional-cardiology-advisory-group-minutes-2017-08.pdf

Interventional Cardiology Advisory Group Meeting held 23 August 2017 (minutes for web publishing) In consideration of the upcoming request for proposals for permanent coronary drug eluting stents (DES) PHARMAC is publishing the relevant portions of the minutes of the Interventional Cardiology Adviso...

9 Results of Cost-Utility Analysis | PHARMAC

https://www.pharmac.govt.nz/assets/_generated_pdfs/9-results-of-cost-utility-analysis-2071.pdf

9 Results of Cost-Utility Analysis < previous (https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/pfpa/8-discounting/) | next > (https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/pfpa/10-sensitivity-analysis/) Key Recommendation: The resul...

1

https://www.pharmac.govt.nz/assets/ptac-ophthalmology-subcommittee-minutes-2017-09.pdf

Ophthalmology Subcommittee of the Pharmacology and Therapeutics Advisory Committee (PTAC) Meeting held on 20 September 2017 (minutes for web publishing) Ophthalmology Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee...

2011-12 Statement of Intent - Final (approved by Board)

https://www.pharmac.govt.nz/assets/statement-of-intent-2011-12-2013-14.pdf

Pharmaceutical Management Agency Statement of Intent 2011/12 - 2013/14 TABLE OF CONTENTS PART 1 ................................................................................................................................2 PHARMAC – our role and contribution to health outcomes ......................

DRAFT

https://www.pharmac.govt.nz/assets/annual-report-2010-2011.pdf

E.59 Pharmaceutical Management Agency Annual Report For the year ended 30 June 2011 Presented to the House of Representatives pursuant to Section 150(3) of the Crown Entities Act 2004 CONTENTS CHAIR’S REPORT ...............................................................................................

1

https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2017-12.pdf

Anti-Infective Subcommittee of the Pharmacology and Therapeutics Advisory Committee (PTAC) Meeting held on 2 November 2017 (minutes for web publishing) Anti-Infective Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee...

statement-of-intent-2009-10.pdf

https://www.pharmac.govt.nz/assets/statement-of-intent-2009-10.pdf

Pharmaceutical Management Agency Statement of Intent 2009/10 TABLE OF CONTENTS OVERVIEW OF PHARMAC ..............................................................................................1 OUR CONTRIBUTION TO THE MEDICINES SYSTEM....................................................1 OUR FORM AN...

Statement of Intent

https://www.pharmac.govt.nz/2002/07/26/SOI.pdf

Pharmaceutical Management Agency (PHARMAC) Statement of Intent 1 July 2001 to 30 June 2002 2 FOREWORD The Pharmaceutical Management Agency (PHARMAC) has had its funding confirmed for the 2001/02 year through the Crown Funding Agreement (dated 3 December 2001) and has prepared this Statement of Inten...

Microsoft Word - 358_01_.DOC

https://www.pharmac.govt.nz/2006/09/27/SOI2006.pdf

PHARMACEUTICAL MANAGEMENT AGENCY (PHARMAC) Statement of Intent 2006/07 TABLE OF CONTENTS FOREWORD..................................................................................................................... 3 PART ONE: PHARMAC OVERVIEW AND STRATEGIC DIRECTION .......................... 4 INT...

FOREWORD

https://www.pharmac.govt.nz/assets/statement-of-intent-2012-13-2014-15.pdf

Pharmaceutical Management Agency Statement of Intent 2012/13 – 2014/15 PHARMAC Statement of Intent 2012/13—2014/15 PHARMAC Statement of Intent 2012/13-2014/15 i INTRODUCTION PHARMAC has been successful in its core role of making decisions on behalf of District Health Boards (DHBs) about which medici...

annual-report-2015-2016.pdf

https://www.pharmac.govt.nz/assets/annual-report-2015-2016.pdf

E.59 Pharmaceutical Management Agency Annual Report For the year ended 30 June 2016 Presented to the House of Representatives pursuant to Section 150(3) of the Crown Entities Act 2004 E.59 ____________________________________________________________________________ Annual Report of Pharmaceutical Ma...

27 May 2003

https://www.pharmac.govt.nz/assets/notification-2012-11-05-decision-regarding-novartis-proposal.pdf

5 November 2012 Decision on proposal for various Novartis products. PHARMAC is pleased to announce the approval of an agreement with Novartis New Zealand Limited for Neoral, Aclasta, Zometa and Risedronate Sandoz. This was the subject of a consultation letter dated 27 September 2012. In summary, the...

DRAFT

https://www.pharmac.govt.nz/2006/11/07/AR06.pdf

- 1 - E.59 ___________________________________________________________________________ Annual Report of Pharmaceutical Management Agency (PHARMAC) for the year ended 30 June 2006 ____________________________________________________________________ Presented to the House of Representatives pursuant t...

1

https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2017-11.pdf

Anti-Infective Subcommittee of the Pharmacology and Therapeutics Advisory Committee (PTAC) Meeting held on 2 November 2017 (minutes for web publishing) Anti-Infective Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee...

5 Transformation of Evidence

https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/pfpa/5-transformation-of-evidence/

5 Transformation of Evidence < previous | next > 5.1   Transformation of Clinical Evidence Key Recommendation: Clinical trials should be analysed using data from the intention-to-treat (ITT) population. All statistically significant clinical events should be included in base-case analyses. For clini...

reporting-2013-14-pharmac-performance-q3.pdf

https://www.pharmac.govt.nz/assets/reporting-2013-14-pharmac-performance-q3.pdf

PHARMAC Performance 2013/14 Performance data to 31 March 2013 Pharmaceutical budget management Combined Pharmaceutical Budget (CPB) 2013/14: $795 million. The planned CPB expenditure for the 2013/14 financial year is $805.02 million. This would require PHARMAC to pay DHBs $10.02 million from the DPF...

statement-of-intent-2013-14-2015-16.pdf

https://www.pharmac.govt.nz/assets/statement-of-intent-2013-14-2015-16.pdf

Pharmaceutical Management Agency Statement of Intent 2013/14 – 2015/16 PHARMAC Statement of Intent 2013/14—2015/16 PHARMAC Statement of Intent 2013/14-2015/16 i INTRODUCTION PHARMAC has defined five strategic goals – one of these, `value from extended functions’, is our dominant theme in 2013/14. PH...

Microsoft Word - 2011-12 Annual Report.doc

https://www.pharmac.govt.nz/assets/annual-report-2011-2012.pdf

E.59 Pharmaceutical Management Agency Annual Report For the year ended 30 June 2012 CONTENTS CHAIR’S REPORT ............................................................................................................ 2 OVERVIEW OF PHARMAC ................................................................

1

https://www.pharmac.govt.nz/assets/ptac-transplant-immunosuppressant-subcommittee-minutes-2008-09.pdf

Transplant Immunosuppressant Subcommittee of PTAC meeting held 4 September 2008 (minutes for web publishing) Transplant Immunosuppressant Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and PTAC Subcommittee...